Related Experiment Video
Updated: Feb 3, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic
Frederik Birkebæk Thomsen1, Cecilia Bosco2, Hans Garmo2,3
1a Copenhagen Prostate Cancer Center, Department of Urology , Rigshospitalet, University of Copenhagen , Copenhagen , Denmark.
Background:
In randomised controlled trials, men with advanced, non-metastatic prostate cancer (PCa) treated with anti-androgen monotherapy (AA) had similar all-cause mortality as men treated with gonadotropin-releasing hormone (GnRH) agonists. Using real-world evidence (i.e., observational data), we aimed to further assess the difference in mortality between these two drug categories.
Material And Methods:
We emulated a trial using data from Prostate Cancer data Base Sweden 3.0. We specifically focused on men diagnosed in 2006-2012 with high-risk PCa who had no distant metastasis. They either received primary hormonal therapy with AA (n = 2078) or GnRH agonists (n = 4878) who were followed for a median time of 5 years. Risk of death from PCa and other causes was assessed using competing risk analyses and Cox proportional hazards regression analyses, including propensity score matching.
Results:
The cumulative 5-year PCa mortality was lower for men treated with AA (16% [95% confidence interval, CI, 15-18%]) than men treated with GnRH agonists (22% [95% CI 21-24%]). The 5-year other cause mortality was also lower for men on AA (17% [95% CI 15-19%] compared to men on GnRH agonists (27% [95% CI 25-28%]). In regression analyses, the risk of PCa death was similar, GnRH agonists versus AA (reference), hazard ratio (HR) 1.08 (95% CI 0.95-1.23), but the risk of death from all causes was higher for men on GnRH agonists, HR 1.23 (95% CI 1.13-1.34). Consistent results were seen in the propensity score-matched cohort.
Conclusion:
Our results indicate that the use of AA as primary hormonal therapy in men with high-risk non-metastatic PCa does not increase PCa-specific mortality compared to GnRH. Using AA instead of GnRH agonists may result in shorter time on/exposure to GnRH-treatment, which may reduce the risk of adverse events associated with this treatment.
Insights
Men with high-risk prostate cancer (PCa) receiving anti-androgen monotherapy (AA) had lower mortality than those on gonadotropin-releasing hormone (GnRH) agonists. AA therapy did not increase PCa-specific mortality, suggesting potential benefits over GnRH agonists.
Area of Science:
- Oncology
- Pharmacology
- Real-world evidence studies
Background:
- Randomized controlled trials (RCTs) show similar all-cause mortality for advanced, non-metastatic prostate cancer (PCa) patients treated with anti-androgen monotherapy (AA) versus gonadotropin-releasing hormone (GnRH) agonists.
- Real-world data is needed to further compare mortality between these treatment categories.
Purpose of the Study:
- To assess the difference in all-cause and PCa-specific mortality between men with high-risk, non-metastatic PCa treated with AA versus GnRH agonists using real-world data.
Main Methods:
- A real-world trial emulation using data from Prostate Cancer data Base Sweden 3.0 (2006-2012).
- Focused on men with high-risk, non-metastatic PCa receiving primary hormonal therapy with AA (n=2078) or GnRH agonists (n=4878).
- Utilized competing risk analyses and propensity score matching for mortality risk assessment over a median follow-up of 5 years.
Main Results:
- Cumulative 5-year PCa mortality was lower with AA (16%) compared to GnRH agonists (22%).
- Cumulative 5-year other-cause mortality was lower with AA (17%) versus GnRH agonists (27%).
- Regression analyses showed similar PCa death risk (HR 1.08) but higher all-cause mortality risk with GnRH agonists (HR 1.23) versus AA.
Conclusions:
- Anti-androgen monotherapy (AA) as primary hormonal therapy for high-risk, non-metastatic PCa does not increase PCa-specific mortality compared to GnRH agonists.
- Using AA may lead to reduced exposure to GnRH-treatment, potentially lowering the risk of associated adverse events.
More Related Videos
09:30Dual Somatic Recordings from Gonadotropin-Releasing Hormone GnRH Neurons Identified by Green Fluorescent Protein GFP in Hypothalamic Slices
Published on: February 23, 2010
08:54Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer
Published on: June 13, 2019
Related Concept Videos
Types of Hormones
Types of Hormones
Steroids and eicosanoids fall under the category of lipid-soluble hormones. Steroids are derived from cholesterol and feature four interconnected carbon rings with variable side chains. Notable examples include estradiol from ovaries and testosterone from testes, exemplifying the critical roles of these lipid-soluble hormones in reproductive physiology. Eicosanoids, derived...
Hormonal Regulation
Hormonal Regulation
Observational Studies
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...
Plant Hormones